For the Inventor, By the Inventor

Enter assignee name

Schlieren, Switzerland

Neurimmune Holding Ag

Calculating rank

USPTO Granted Patents = 16

EPO Patents = 5

Trademarks = 3

Forward Citations = 16

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Jan Grimm (16 out of 38 patents)

Fabio Montrasio (5 out of 10 patents)

Marcel Maier (4 out of 7 patents)

4. Fabrice Heitz (4 out of 4 patents)

5. Maria Grazia Barenco Montrasio (3 out of 6 patents)

6. Roger Nitsch (3 out of 28 patents)

7. Christoph Hock (3 out of 20 patents)

8. Tobias Welt (3 out of 3 patents)

9. Aubin Michalon (3 out of 3 patents)

10. Feng Chen (3 out of 7 patents)

11. Ioana Combaluzier (3 out of 3 patents)

12. Benoit Combaluzier (3 out of 3 patents)

13. Ivan Jelcic (3 out of 3 patents)

14. Roland Martin (3 out of 11 patents)

15. Jordan Mcafoose (2 out of 2 patents)

16 patents: Sort by Forward Citations

1. 12234281 - Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor (2025-02-25),

2. 11608372 - Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases (2023-03-21),

3. 11401325 - Human-derived anti-huntingtin (HTT) antibodies and uses thereof (2022-08-02),

4. 11352441 - Human anti-SOD1 antibodies (2022-06-07),

5. 11180545 - Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor (2021-11-23),

6. 10961322 - Human-derived anti-dipeptide repeats (DPRs) antibody (2021-03-30),

7. 10882902 - Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof (2021-01-05),

8. 10544213 - Compounds capable of antagonizing islet amyloid polypeptide (IAPP) induced beta-cell damage and impaired glucose tolerance (2020-01-28),

9. 10450365 - Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases (2019-10-22),

10. 10392447 - Human-derived anti-dipeptide repeats (DPRs) antibody (2019-08-27),

11. 10344097 - Human anti-SOD1 antibodies (2019-07-09),

12. 10344080 - Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor (2019-07-09),

13. 10072074 - Human islet amyloid polypeptide (HIAPP) specific antibodies and uses thereof (2018-09-11),

14. 9771413 - Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases (2017-09-26),

15. 9475866 - Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof (2016-10-25),

Company Overview

Neurimmune Holding AG is a biopharmaceutical company based in Schlieren, Switzerland, specializing in the development of innovative therapies for neurodegenerative diseases. The company focuses on harnessing its proprietary antibody technology to create treatments targeting conditions such as Alzheimer's disease and other related disorders. With a strong emphasis on research and development, Neurimmune collaborates with various academic and industry partners to advance its therapeutic candidates, aiming to improve patient outcomes in the field of neurology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

16 Patents

#10 in Schlieren

#764 in Switzerland

#37,887 in the World

Schlieren, Switzerland

Neurimmune Holding Ag

Forward Citations = 16

16 inventors:

Jan Grimm (16 out of 38 patents)

Fabio Montrasio (5 out of 10 patents)

Marcel Maier (4 out of 7 patents)

4. Fabrice Heitz (4 out of 4 patents)

5. Maria Grazia Barenco Montrasio (3 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Neurimmune Holding Ag. Retrieved from https://idiyas.com/company/neurimmune-holding-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…